E10 E11
Conditions
Interventions
Group 1: no ultrasound of injections sites, unguided recommendation for change of injection sites
Group 2: ultrasound of injection sites and resulting individual recommendation to avoid/use certain in
Sponsors
Universitätsklinikum Düsseldorf, Zentrum für Kinder- und Jugendmedizin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Insulin-dependent diabetes mellitus, Insulin therapy as multiple daily injections (MDI), age =18 years, patient consent, HbA1c values ??between 5.5% and 11.0%, currently using or willing to use a Flash Glucose Monitoring System (FGM) or a Continuous Glucose Monitoring System (CGM) for continuous glucose measurement during the study period.
Exclusion criteria
Exclusion criteria: Hypertrophic or atrophic lipodystrophies visible or diagnosed by palpation, patch allergies that prevent wearing a CGM / FGM sensor, severe hypoglycaemia unawareness, insulin pump therapy, current cortisone therapy or medication that significantly influences the usual diabetes therapy, inadequate knowledge / experience with dose adjustment of the previously used insulin and treatment of hyper- and hypoglycaemia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of postprandial (2h) glucose levels pre- and post ultrasound in FGM/CGM data (14 days). | — |
Secondary
| Measure | Time frame |
|---|---|
| Longer time in range (TIR, BG ??between 70 and 180 mg / dl), lower basal and average glucose levels, less glucose fluctuations, lower HbA1c level in the next visit. | — |
Countries
Germany
Contacts
Public ContactDirk Sandig
Hospital zum Heiligen Geist Kempen
Outcome results
None listed